The Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D) was a randomized study with 2,368 patients with T2D and SMI comparing revascularization versus intensive medical therapy, showed no differences on reducing rates of death and cardiovascular events among patients undergoing prompt revascularization and those undergoing medical therapy or between strategies insulin sensitizers or insulin provision [123]. Here, INS is linked to diabetes mellitus.